Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUV1647 in erythropoietic protoporphyria
ACTRN12606000535572Phase 2Terminated
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Sep 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Afamelanotide in erythropoietic protoporphyria (EPP), sponsored by Clinuvel Pharmaceuticals. Started Sep 2006; status: terminated.
02
Drugs
Afamelanotide
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on ACTRN12606000535572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000535572.